Literature DB >> 26380058

Intrahepatic therapy for liver-dominant metastatic colorectal cancer.

Kerlijne De Groote1, Hans Prenen1.   

Abstract

In patients with metastatic colorectal cancer, the liver is the most common site of metastatic disease. In patients with liver-dominant disease, consideration needs to be given to locoregional treatments such as hepatic arterial infusion chemotherapy, transarterial chemoembolisation and selective internal radiation therapy because hepatic metastases are a major cause of liver failure especially in chemorefractory disease. In this review we provide insights on the published literature for locoregional treatment of liver metastases in metastatic colorectal cancer.

Entities:  

Keywords:  Chemoembolization; Colorectal cancer; Intrahepatic treatment; Liver metastases; Radioembolisation

Year:  2015        PMID: 26380058      PMCID: PMC4569592          DOI: 10.4251/wjgo.v7.i9.148

Source DB:  PubMed          Journal:  World J Gastrointest Oncol


  24 in total

1.  Is there a new drug beyond floxuridine for intra-arterial hepatic chemotherapy in liver metastases from colorectal cancer?

Authors:  G Fiorentini; S Rossi; P Bernardeschi; M Cantore; S Guadagni
Journal:  J Clin Oncol       Date:  2005-03-20       Impact factor: 44.544

2.  Trans-arterial chemoembolization of metastatic colorectal carcinoma to the liver adopting DC Bead®, drug-eluting bead loaded with irinotecan: results of a phase II clinical study.

Authors:  Camillo Aliberti; Giammaria Fiorentini; Pier Carlo Muzzio; Fabio Pomerri; Massimo Tilli; Sergio Dallara; Giorgio Benea
Journal:  Anticancer Res       Date:  2011-12       Impact factor: 2.480

3.  Phase III trial comparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapy.

Authors:  Alain Hendlisz; Marc Van den Eynde; Marc Peeters; Geert Maleux; Bieke Lambert; Jaarke Vannoote; Katrien De Keukeleire; Chris Verslype; Luc Defreyne; Eric Van Cutsem; Philippe Delatte; Thierry Delaunoit; Nicola Personeni; Marianne Paesmans; Jean-Luc Van Laethem; Patrick Flamen
Journal:  J Clin Oncol       Date:  2010-06-21       Impact factor: 44.544

4.  Randomised phase 2 trial of SIR-Spheres plus fluorouracil/leucovorin chemotherapy versus fluorouracil/leucovorin chemotherapy alone in advanced colorectal cancer.

Authors:  Guy Van Hazel; Anthony Blackwell; James Anderson; David Price; Paul Moroz; Geoff Bower; Giuseppe Cardaci; Bruce Gray
Journal:  J Surg Oncol       Date:  2004-11-01       Impact factor: 3.454

Review 5.  Safety and efficacy of trans arterial chemoembolization with drug-eluting beads in hepatocellular cancer: a systematic review.

Authors:  Robert Martin; David Geller; Joseph Espat; David Kooby; Marty Sellars; Robert Goldstein; David Imagawa; Charles Scoggins
Journal:  Hepatogastroenterology       Date:  2012 Jan-Feb

6.  Intrahepatic arterial versus intravenous fluorouracil and folinic acid for colorectal cancer liver metastases: a multicentre randomised trial.

Authors:  David J Kerr; Colin S McArdle; Jonathan Ledermann; Irving Taylor; David J Sherlock; Peter M Schlag; John Buckels; David Mayer; Dionne Cain; Richard J Stephens
Journal:  Lancet       Date:  2003-02-01       Impact factor: 79.321

7.  FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial.

Authors:  Volker Heinemann; Ludwig Fischer von Weikersthal; Thomas Decker; Alexander Kiani; Ursula Vehling-Kaiser; Salah-Eddin Al-Batran; Tobias Heintges; Christian Lerchenmüller; Christoph Kahl; Gernot Seipelt; Frank Kullmann; Martina Stauch; Werner Scheithauer; Jörg Hielscher; Michael Scholz; Sebastian Müller; Hartmut Link; Norbert Niederle; Andreas Rost; Heinz-Gert Höffkes; Markus Moehler; Reinhard U Lindig; Dominik P Modest; Lisa Rossius; Thomas Kirchner; Andreas Jung; Sebastian Stintzing
Journal:  Lancet Oncol       Date:  2014-07-31       Impact factor: 41.316

8.  Transarterial chemoembolization of unresectable systemic chemotherapy-refractory liver metastases from colorectal cancer: long-term results over a 10-year period.

Authors:  Tatjana Gruber-Rouh; Nagy N N Naguib; Katrin Eichler; Hanns Ackermann; Stephan Zangos; Jörg Trojan; Martin Beeres; Marc Harth; Boris Schulz; Nour-Eldin Nour-Eldin A; Thomas J Vogl
Journal:  Int J Cancer       Date:  2013-09-03       Impact factor: 7.396

9.  A randomized trial of intrahepatic infusion of fluorodeoxyuridine with dexamethasone versus fluorodeoxyuridine alone in the treatment of metastatic colorectal cancer.

Authors:  N Kemeny; K Seiter; D Niedzwiecki; D Chapman; E Sigurdson; A Cohen; J Botet; P Oderman; P Murray
Journal:  Cancer       Date:  1992-01-15       Impact factor: 6.860

10.  Alternating systemic and hepatic artery infusion therapy for resected liver metastases from colorectal cancer: a North Central Cancer Treatment Group (NCCTG)/ National Surgical Adjuvant Breast and Bowel Project (NSABP) phase II intergroup trial, N9945/CI-66.

Authors:  Steven R Alberts; Mark S Roh; Michelle R Mahoney; Michael J O'Connell; David M Nagorney; Lawrence Wagman; Thomas C Smyrk; Timothy L Weiland; Lily Lau Lai; Roderich E Schwarz; Roy Molina; Todor Dentchev; John S Bolton
Journal:  J Clin Oncol       Date:  2010-01-04       Impact factor: 44.544

View more
  3 in total

1.  SW43-DOX ± loading onto drug-eluting bead, a potential new targeted drug delivery platform for systemic and locoregional cancer treatment - An in vitro evaluation.

Authors:  Johannes M Ludwig; Yongkang Gai; Lingyi Sun; Guangya Xiang; Dexing Zeng; Hyun S Kim
Journal:  Mol Oncol       Date:  2016-05-21       Impact factor: 6.603

2.  Comparison of overall survival in patients with unresectable hepatic metastases with or without transarterial chemoembolization: A Propensity Score Matching Study.

Authors:  F Y Wang; W Meng; Y Li; T Li; C Y Qin
Journal:  Sci Rep       Date:  2016-10-13       Impact factor: 4.379

3.  Shared liver-like transcriptional characteristics in liver metastases and corresponding primary colorectal tumors.

Authors:  Jun Cheng; Xuekun Song; Lu Ao; Rou Chen; Meirong Chi; You Guo; Jiahui Zhang; Hongdong Li; Wenyuan Zhao; Zheng Guo; Xianlong Wang
Journal:  J Cancer       Date:  2018-04-06       Impact factor: 4.207

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.